You are here


A Drug Forecast article in the October 2015 issue of P&T (“Edoxaban [Savaysa]: a Factor Xa Inhibitor,” pages 651–655, 696) incorrectly characterized a boxed warning for edoxaban. The article should have said that edoxaban’s efficacy is reduced in nonvalvular atrial fibrillation patients with a creatinine clearance (CrCl) greater than 95 mL/min. Edoxaban should not be initiated in patients with an estimated CrCl of greater than 95 mL/min due to high-dose edoxaban’s association with an increased risk of ischemic stroke compared to patients treated with warfarin.